CL2022001250A1 - Métodos para tratar el aumento de peso inducido por antisicótidos con miricorilant. - Google Patents
Métodos para tratar el aumento de peso inducido por antisicótidos con miricorilant.Info
- Publication number
- CL2022001250A1 CL2022001250A1 CL2022001250A CL2022001250A CL2022001250A1 CL 2022001250 A1 CL2022001250 A1 CL 2022001250A1 CL 2022001250 A CL2022001250 A CL 2022001250A CL 2022001250 A CL2022001250 A CL 2022001250A CL 2022001250 A1 CL2022001250 A1 CL 2022001250A1
- Authority
- CL
- Chile
- Prior art keywords
- weight gain
- antipsychotic
- medication
- methods
- reduce
- Prior art date
Links
- 230000004584 weight gain Effects 0.000 title abstract 6
- 235000019786 weight gain Nutrition 0.000 title abstract 6
- GVVUZBSCYAVFTI-IYARVYRRSA-N miricorilant Chemical compound FC(F)(F)C1=CC=CC(CC2=C(NC(=O)NC2=O)[C@H]2CC[C@@H](CC2)C2=CC=CC=C2)=C1 GVVUZBSCYAVFTI-IYARVYRRSA-N 0.000 title abstract 3
- 229940121462 miricorilant Drugs 0.000 title abstract 3
- 229940124604 anti-psychotic medication Drugs 0.000 abstract 4
- 230000000561 anti-psychotic effect Effects 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- YJDDXMSIMBMMGY-UHFFFAOYSA-N 2-cyclohexylpyrimidine Chemical compound C1CCCCC1C1=NC=CC=N1 YJDDXMSIMBMMGY-UHFFFAOYSA-N 0.000 abstract 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 229960004170 clozapine Drugs 0.000 abstract 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960005017 olanzapine Drugs 0.000 abstract 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 1
- 229960001534 risperidone Drugs 0.000 abstract 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Child & Adolescent Psychology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se divulgan métodos y composiciones para tratar un sujeto que está en riesgo de padecer o padece aumento de peso inducido por antisicóticos. Los métodos incluyen la administración de un modulador de los receptores de glucocorticoides GRM de cicloehexil pirimidina como miricorilant , CORT 118335, a un paciente que recibe o que ha recibido o que se espera que reciba un medicamento antisicótico como olanzapina, risperidona, clozapina u otro medicamento antisicótico que induce el aumento de peso. Los GRM, por ejemplo, miricorilant, se puede administrar por via oral. La administración de dicho GRM junto con medicamento antisicótico puede reducir la cantidad de peso o reducir la tasa de aumento de peso o prevenir el aumento de peso, de otro modo debido al medicamento solo. Los métodos pueden revertir el aumento de peso en un paciente a quien se administró un medicamento antisicótico previamente. La administración de dicho GRM con el medicamento antisicótico puede reducir o reducir el aumento o prevenir el aumento o revertir el aumento en la resistencia a la insulina o los noveles de enzimas hepáticas, AST, ALT, Los triglicéridos o la insulina en la sangre.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946957P | 2019-12-11 | 2019-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022001250A1 true CL2022001250A1 (es) | 2023-02-10 |
Family
ID=76316599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022001250A CL2022001250A1 (es) | 2019-12-11 | 2022-05-12 | Métodos para tratar el aumento de peso inducido por antisicótidos con miricorilant. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11903945B2 (es) |
| EP (1) | EP4072556A4 (es) |
| JP (1) | JP2023505948A (es) |
| KR (1) | KR20220113767A (es) |
| CN (1) | CN114929229A (es) |
| AU (1) | AU2020400061A1 (es) |
| CA (1) | CA3158745A1 (es) |
| CL (1) | CL2022001250A1 (es) |
| IL (1) | IL291775A (es) |
| MX (1) | MX2022006633A (es) |
| WO (1) | WO2021119432A1 (es) |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (es) | 1954-11-30 | 1957-04-11 | ||
| DE3011809A1 (de) | 1980-03-27 | 1981-10-01 | Cassella Ag, 6000 Frankfurt | Pyrimidyl-chinazoline, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und ihre verwendung |
| IL72729A (en) | 1983-09-26 | 1988-02-29 | Lilly Co Eli | Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them |
| JPS6417555A (en) | 1987-07-13 | 1989-01-20 | Tokyo Electric Co Ltd | Facsimile |
| US5008267A (en) | 1988-10-29 | 1991-04-16 | Mitsui Toatsu Chemicals, Incorporated | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same |
| GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| JPH06128238A (ja) | 1992-10-20 | 1994-05-10 | Mitsui Toatsu Chem Inc | 新規ピリミジンジオン誘導体 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| CN1043641C (zh) | 1993-08-06 | 1999-06-16 | 史密丝克莱恩比彻姆制药股份公司 | 氢化异喹啉衍生物 |
| EP0722732A1 (en) | 1995-01-24 | 1996-07-24 | Mitsui Toatsu Chemicals, Inc. | Long-acting drug formulation containing pyrimidinedione derivatives |
| US5929058A (en) | 1996-12-24 | 1999-07-27 | Zymogenetics, Inc. | Treatment agents and methods for treating type II diabetes and symptoms of type II diabetes |
| JP2001518509A (ja) | 1997-10-06 | 2001-10-16 | ザ ボード オブ トラスティーズ オブ レランド スタンフォード ジュニア ユニバーシティ | グルココルチコイド関連機能不全に関連した精神病の処置のための方法。 |
| EP1061919A4 (en) | 1998-03-10 | 2002-09-04 | Res Triangle Inst | NEW OPIATES, METHOD FOR THE PRODUCTION AND USE THEREOF |
| WO1999059596A1 (en) | 1998-05-15 | 1999-11-25 | The Board Of Trustees Of Leland Stanford Junior University | Glucocorticoid receptor antagonists for the treatment of dementia |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| EP1201660B1 (en) | 2000-10-30 | 2005-08-31 | Pfizer Products Inc. | Glucocorticoid receptor modulators |
| GB0029100D0 (en) | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
| AU2002355929A1 (en) | 2001-07-17 | 2003-03-03 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| DK1408981T3 (da) | 2001-07-23 | 2009-01-12 | Corcept Therapeutics Inc | Fremgangsmåder til forebyggelse af vægtforögelse som fölge af antipsykotiske midler |
| AU2003214879B2 (en) | 2002-01-22 | 2008-02-07 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| WO2003084936A2 (en) | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TWI327915B (en) * | 2003-06-12 | 2010-08-01 | Organon Nv | Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight |
| EP1660081A1 (en) | 2003-09-03 | 2006-05-31 | Wyeth | Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and pharmaceutical compositions containing the same |
| DK1761497T3 (da) | 2004-01-09 | 2008-11-03 | Corcept Therapeutics Inc | Azadecalinglucocorticoidreceptormodulatorer |
| CA2558899C (en) | 2004-03-09 | 2013-02-05 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| CA2572544C (en) | 2004-07-02 | 2013-02-26 | Corcept Therapeutics, Inc. | Modified pyrimidine glucocorticoid receptor modulators |
| KR100931411B1 (ko) | 2005-04-05 | 2009-12-10 | 에프. 호프만-라 로슈 아게 | 1ｈ-피라졸 4-카복실아미드, 이의 제조 방법, 및 이의 11베타-하이드록시스테로이드 탈수소효소로서의 용도 |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| CN1965840A (zh) * | 2005-11-18 | 2007-05-23 | 科塞普特治疗公司 | 预防由抗精神病药物引起的体重增加的方法 |
| US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| ES2448839T3 (es) | 2007-11-01 | 2014-03-17 | Bristol-Myers Squibb Company | Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos |
| CA2622696A1 (en) * | 2007-11-05 | 2009-05-05 | Diane Mcintosh | Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs |
| WO2010132445A1 (en) | 2009-05-12 | 2010-11-18 | Corcept Therapeutics, Inc. | Solid forms and process for preparing |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| US8598154B2 (en) | 2010-08-27 | 2013-12-03 | Corcept Therapeutics, Inc. | Pyridyl-amine fused azadecalin modulators |
| US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| JP6039587B2 (ja) * | 2011-03-18 | 2016-12-07 | コーセプト セラピューティクス， インコーポレイテッド | ピリミジンシクロヘキシルグルココルチコイドレセプター調節因子 |
| SI3329919T1 (sl) | 2011-11-11 | 2020-02-28 | Gilead Apollo, Llc | Inhibitorji ACC in njihove uporabe |
| WO2013130420A1 (en) | 2012-02-27 | 2013-09-06 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| WO2013174962A1 (en) | 2012-05-25 | 2013-11-28 | Janssen R&D Ireland | Uracyl spirooxetane nucleosides |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| KR102062640B1 (ko) | 2012-05-25 | 2020-01-06 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 헤테로아릴-케톤 융합된 아자데칼린 글루코코르티코이드 수용체 조절제 |
| PL3074011T3 (pl) | 2013-11-25 | 2020-01-31 | Corcept Therapeutics Incorporated | Połączone fuzyjnie oktahydro związki azadekaliny jako modulatory receptora glukokortykoidowego |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
-
2020
- 2020-12-11 MX MX2022006633A patent/MX2022006633A/es unknown
- 2020-12-11 IL IL291775A patent/IL291775A/en unknown
- 2020-12-11 CN CN202080086165.9A patent/CN114929229A/zh active Pending
- 2020-12-11 KR KR1020227023596A patent/KR20220113767A/ko unknown
- 2020-12-11 AU AU2020400061A patent/AU2020400061A1/en active Pending
- 2020-12-11 WO PCT/US2020/064520 patent/WO2021119432A1/en unknown
- 2020-12-11 JP JP2022528536A patent/JP2023505948A/ja active Pending
- 2020-12-11 EP EP20900160.1A patent/EP4072556A4/en active Pending
- 2020-12-11 US US17/119,582 patent/US11903945B2/en active Active
- 2020-12-11 CA CA3158745A patent/CA3158745A1/en active Pending
-
2022
- 2022-05-12 CL CL2022001250A patent/CL2022001250A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20210177848A1 (en) | 2021-06-17 |
| AU2020400061A1 (en) | 2022-04-14 |
| WO2021119432A1 (en) | 2021-06-17 |
| KR20220113767A (ko) | 2022-08-16 |
| CA3158745A1 (en) | 2021-06-17 |
| CN114929229A (zh) | 2022-08-19 |
| US11903945B2 (en) | 2024-02-20 |
| JP2023505948A (ja) | 2023-02-14 |
| IL291775A (en) | 2022-06-01 |
| EP4072556A4 (en) | 2024-01-03 |
| MX2022006633A (es) | 2022-06-24 |
| EP4072556A1 (en) | 2022-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pandina et al. | A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia | |
| McEvoy et al. | Original Research Effectiveness of Lurasidone in Patients With Schizophrenia or | |
| BR112015010203A8 (pt) | composição para a prevenção ou tratamento de diabetes, complicações diabéticas ou diabesidade, uso de um conjugado análogo da oxintomodulina, e, método para a preparação de um conjugado análogo da oxintomodulina | |
| MX2022007012A (es) | Uso de un agonista doble del receptor de glp-1/glucagon de larga accion para el tratamiento de la enfermedad de higado graso no alcoholico. | |
| NO20072931L (no) | Forbedret doseringsregime av temozolomid for behandling av kreft basert pa pasientens MGMT-niva | |
| CY1118017T1 (el) | Υποβαλλοντας σε αγωγη την ανεπαρκεια και το ελλειμμα βιταμινης d με 25-υδροξυβιταμινη d2 και 25-υδροξυβιταμινη d3 | |
| BRPI1007945C1 (pt) | composição farmacêutica, comprimido, e, usos de nitazoxanida ou de um seu análogo | |
| CR20190433A (es) | Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1 | |
| Torres et al. | Does Silybum marianum play a role in the treatment of chronic hepatitis C? | |
| ES2732062T3 (es) | Uso de cannabinoides en el tratamiento de enfermedades musculoesqueléticas degenerativas | |
| BRPI0509710A8 (pt) | Formulação de liberação controlada para administração oral de inibidor de hmg-coa redutase e método para preparação da mesma | |
| CR20110243A (es) | Tratamiento de pirfenidona para pacientes con función hepática. | |
| AR079057A1 (es) | Triaosilceramida urinaria (gb3) como marcador de enfermedad cardiaca | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| García et al. | Concentrations in plasma clozapine levels in schizophrenic and schizoaffective patients | |
| BR112013010829A2 (pt) | composição farmacêutica intravenenosa para proporcionar alívio da dor e / ou da inflamação, uso e método da mesma | |
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| BRPI0513938A (pt) | composição farmacêutica contendo drospirenona e etinilestradiol | |
| CR8059A (es) | Composicion farmaceutica en forma de hidrogel para administracion transdermica de sustancias activas | |
| Feduccia et al. | Heat increases MDMA-enhanced NAcc 5-HT and body temperature, but not MDMA self-administration | |
| Gutierrez-Rojas et al. | Prevalence of metabolic syndrome in Spanish patients with schizophrenia and overweight. The CRESSOB Study | |
| BR0308229A (pt) | Medicamentos contendo ingredientes ativos que diminuem o nìvel de colesterol com liberação do ingrediente ativo de tempo tardio | |
| CL2022001250A1 (es) | Métodos para tratar el aumento de peso inducido por antisicótidos con miricorilant. | |
| CO6311076A2 (es) | Una composición que comprende 2-n-butil-3-[4-(3-di-n-butilaminopropoxi)benzoil]-5-metilsulfonamido-benzofurano y sus sales aceptables farmacéuticamente |